NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the body. It is essential for converting food into ATP — the energy currency of the cell — and it serves as a substrate for sirtuins and PARP enzymes that regulate DNA repair, mitochondrial function, and cellular stress response. NAD+ levels decline measurably with age, with chronic disease, with metabolic dysfunction, and with sustained oxidative stress. NAD+ IV therapy at Regeneris Therapy is a physician-supervised infusion of pharmaceutical-grade NAD+ designed to raise circulating levels in patients who have a defined goal — energy, cognition, recovery, longevity-stack integration. We are explicit that NAD+ is not a cure for aging, not a treatment for any specific disease, and not a substitute for sleep, exercise, and nutrition. It is, in the right patient, a measurable metabolic intervention with a real effect profile.
What NAD+ actually is and why levels matter
Every cell in your body runs on ATP, the universal energy currency. ATP is produced through cellular respiration in the mitochondria, and the entire pathway depends on NAD+ as an electron acceptor — without NAD+ in adequate supply, mitochondrial energy production slows, and downstream functions that depend on energy (DNA repair, protein quality control, neurotransmitter synthesis, immune function) slow with it. NAD+ also serves as a required substrate for two enzyme families: sirtuins (SIRT1 through SIRT7), which regulate longevity-related gene expression and mitochondrial biogenesis, and PARP enzymes, which repair DNA damage. When NAD+ is depleted, sirtuins and PARPs cannot do their work effectively, and cellular maintenance suffers. Multiple human and animal studies have documented that NAD+ levels in tissue decline 30 to 50% by age 50 and even more by age 70. This decline is not the whole story of aging, but it is one of the measurable molecular features of it. Raising NAD+ levels by clinical infusion is a way to address this specific lever — see our broader anti-aging hub for context on how NAD+ fits the larger picture.
Why IV instead of oral NMN, NR, or niacinamide
Oral NAD+ precursors — nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and high-dose niacinamide — are widely sold and have a growing evidence base for raising NAD+ levels modestly when taken consistently. They are a reasonable maintenance strategy and we sometimes recommend them. But there are three reasons IV NAD+ is a different intervention. First, bioavailability: oral NAD+ itself is destroyed in the gut, and even the precursor forms have variable absorption and significant first-pass metabolism that limits how much actually reaches systemic circulation. IV NAD+ bypasses this entirely — the dose you receive is the dose that reaches your bloodstream. Second, plasma kinetics: a clinical IV dose produces an order-of-magnitude higher peak plasma NAD+ than even high oral precursor doses, which translates to acute saturation of NAD+-dependent pathways that oral cannot achieve. Third, clinical use case: for patients who want a defined loading protocol (often 3 to 10 infusions over several weeks), IV gives a predictable and measurable intervention rather than a slow accumulation. We do not claim IV is universally better than oral — we use both in different contexts.
